SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor ($OPEN) is trending due to a leadership shakeup, including a new CEO from Shopify, sparking significant community interest and high trading volume. Bullish sentiment is fueled by the new CEO's compensation structure that is highly correlated with the stock price appreciating, and potential short squeeze, while bears are warning of an overvalued meme stock and potential for a rug pull. Community members are actively discussing price targets and debating the sustainability of the rally amid evolving real estate market conditions.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The trending of DJT is being driven by community discussions surrounding political events and figures, including reactions to the shooting of Charlie Kirk and ongoing debates about political ideologies.  Conversations include diverse viewpoints, from expressions of support for the MAGA movement to criticisms of perceived misinformation. Some users are also referencing the Epstein files and calling for their release, linking it to prominent political figures.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as community members debate whether the ETF can sustain its climb amid persistent inflation and an upcoming Fed decision. Bullish sentiment remains strong, with many anticipating rate cuts and further upside, while bears warn of an overvalued market and potential pullback. Political events and their impact on the market are also being discussed.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance ($PSKY) is trending amid reports of a potential takeover bid for Warner Bros. Discovery ($WBD), sparking community discussion about the implications of a combined media powerhouse and its impact on competitors like Netflix.  Investors are also excited about the company's new partnerships and initiatives under its new CEO, David Ellison, with many seeing the stock as undervalued.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the following segments: Design Automation, Design IP, and Software Integrity. The Design Automation segment includes silicon design, verification products and services, system integration products and services, digital, custom, and FPGA IC design software, verification software and hardware products, and manufacturing software products. The Software Integrity segment includes a solution for building security and compliance testing into the customers' software development lifecycle and supply chain. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys ($SNPS) is trending due to a significant drop following earnings, with the community debating if it's a buying opportunity or a falling knife. Discussions revolve around the extent of the overreaction and the potential for a short squeeze, given the stock's oversold conditions. Some investors are pointing to analyst ratings and the company's strategic importance in the chip design market as reasons for optimism, while others highlight concerns about trade tensions and competition.

BGSF, Inc. engages in providing consulting, managed services, and professional workforce solutions. It operates through the Property Management and Professional segments. The Property Management segment offers office and maintenance talent in 38 states and D.C. to property management companies responsible for the apartment communities’ and commercial buildings’ day-to-day operations. The Professional segment is involved with specialized talent and business consultants for information technology, managed services, finance, accounting, legal and human resource. The company was founded on August 27, 2007, and is headquartered in Plano, TX.

BGSF Inc

BGSF is trending due to the declaration of a special cash dividend of $2.00 per share, leading to discussions around dividend capture strategies and yield calculations. Community members are comparing it to similar dividend plays like $SOGP, anticipating a potential multi-day run. The dividend follows a recent divestiture, with investors speculating on future capital allocation strategies.

Bonk is the first Solana dog coin for the people, by the people with 50% of the total supply airdropped to the Solana community. The Bonk contributors were tired of toxic “Alameda” tokenomics and wanted to make a fun memecoin where everyone gets a fair shot.

BONK

BONK.X is trending as the community anticipates a potential token burn upon reaching 1 million holders, driving excitement around deflationary mechanics. Discussions also highlight recent Safety Shot news and the broader Solana ecosystem as potential catalysts. Some traders are noting key resistance levels and looking for breakouts.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending due to anticipation surrounding its merger with Strive and the potential acquisition of a significant Bitcoin treasury. The community is buzzing about the possibility of a short squeeze, driven by high short interest and the expectation that shorts must cover after the merger. Investors are also optimistic about Strive's plans to utilize Bitcoin for biotech investments, potentially creating a multi-sector vehicle with considerable upside.

Invesco DB US Dollar Index Trust - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

The UUP ETF, tracking the dollar's strength, is trending amid discussions around potential Federal Reserve rate cuts and their impact on the dollar's value. Community members are analyzing technical patterns and considering options strategies, while also weighing the influence of economic data like CPI and PPI on the dollar's trajectory. Some traders believe gold is overbought and the dollar is oversold, hinting at a possible shift.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending following the announcement of volume shipments of its NVIDIA Blackwell Ultra solutions, signaling potential growth. The community is actively discussing the impact of this news on future earnings and analyst ratings, with many believing SMCI is undervalued. However, some investors remain cautious due to the company's history of internal control issues.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celldex Therapeutics shares slipped in after-hours trading&nbsp;on&nbsp;Tuesday after the biotech said it will stop developing barzolvolimab for eosinophilic esophagitis (EoE).The stock closed down 1.9% at $24.02 on Tuesday and slid another 14.2% to $20.62 in after-hours trading following its Phase 2 EoE update.The decision to pull the plug on the&nbsp;EoE candidate came after&nbsp;the Phase 2 trial hit its primary goal by reducing mast cells in the esophagus, but the depletion failed to bring meaningful improvements for patients.No differences were observed between barzolvolimab and placebo in dysphagia symptom scores, endoscopic assessment of inflammation and fibrosis, or histological reduction in eosinophil infiltration.&nbsp;Celldex said the results provide direct evidence that mast cells are not a primary driver of the disease.The study confirmed barzolvolimab’s favorable safety and tolerability profile at the dosing regimen that was tested, consistent with prior studies where dosing was less frequent.&nbsp;“While we are disappointed in the clinical outcome in EoE, we are proud of our role in advancing the science for patients who need more effective treatment options,” said Chief Executive Officer Anthony Marucci.Marucci added that Celldex remains committed to barzolvolimab’s broader pipeline, with enrollment ongoing in four studies: two Phase 3 trials in chronic spontaneous urticaria and two Phase 2 trials in atopic dermatitis and prurigo nodularis.&nbsp;The company is also finalizing plans to initiate a Phase 3 program in inducible urticaria, covering cold urticaria and symptomatic dermographism.On Stocktwits, retail sentiment for Celldex was ‘bullish’ amid ‘high’ message volume.One user focused on Celldex’s pivot toward chronic spontaneous urticaria (CSU), saying investors are primarily betting on the Phase 3 program after strong Phase 2 data, which they described as better than the current standard of care.&nbsp;They noted that CSU represents a much larger commercial opportunity, with market leader Xolair bringing in more than $4 billion in revenue in 2024.<stembedurl>https://stocktwits.com/TheGunnerAB/message/625855252</stembedurl>Another user suggested the pullback could be a buying opportunity, calling it a good time to add to positions in Celldex.<stembedurl>https://stocktwits.com/StockHunter75/message/625842884</stembedurl><a href="https://stocktwits.com/symbol/CLDX">Celldex’s stock</a> has declined 5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Celldex Therapeutics (CLDX) shares slipped in after-hours trading on Tuesday after the biotech said it will stop developing barzolvolimab for eosinophilic esophagitis. (Photo credit: Getty Images)

Why Are Celldex Shares Tumbling After Hours?

The biotech firm said it would halt development of barzolvolimab in eosinophilic esophagitis following Phase 2 results that met the trial’s primary goal but failed to show clinical benefit. 

Equity

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of +1.16% and -56.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?

scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Retail investor chatter around Celldex Therapeutics spiked on Sunday following new Phase 2 data showing barzolvolimab provided “profound long-term” relief from angioedema in patients with chronic spontaneous urticaria (CSU).Celldex shares closed 4.5% higher at $21.26 on Friday.The company presented updated 52-week results at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Congress in Glasgow, showing that 77% of patients on barzolvolimab were angioedema-free at Week 52.&nbsp;The antibody therapy also showed up to 87% of patients reported “clinically meaningful” improvements in angioedema activity scores (AAS7).Barzolvolimab targets KIT, a receptor tyrosine kinase involved in mast cell regulation.&nbsp;In CSU, mast cells drive persistent inflammation and swelling even after standard antihistamine therapy fails.Patients with severe CSU and angioedema frequently endure disfigurement and debilitating pain, said Diane C. Young, MD, Chief Medical Officer at Celldex.&nbsp;Additional data showed an 86% mean reduction in angioedema activity in the 150 mg group and 82% in the 300 mg every-8-weeks group.&nbsp;Patients remained angioedema-free for 72% of the year-long treatment period.Retail sentiment on platforms such as Stocktwits and Reddit turned sharply bullish over the weekend, with several users highlighting the durability of symptom control and potential differentiation from existing CSU treatments like Novartis’ Xolair.The 208-patient Phase 2 trial had previously met all primary and secondary endpoints at 12 weeks.&nbsp;A global Phase 3 program is underway, targeting antihistamine-refractory CSU patients, including those previously treated with biologics.On Stocktwits, retail sentiment was ‘bearish’ amid ‘extremely high’ message volume.Celldex stock has declined 17.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded

Celldex’s candidate targets KIT, a mast cell receptor tied to CSU inflammation, and had earlier met all key endpoints at 12 weeks.

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock

Latest Ratings for CLDX
 DateFirmActionFromTo Sep 2021JefferiesInitiates Coverage OnBuy Sep 2021HC Wainwright & Co.MaintainsBuy Sep 2021SVB LeerinkInitiates Coverage OnOutperform
 View More...

Analyst Expectations For Celldex Therapeutics's Future

A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics

7 Analysts Have This To Say About Celldex Therapeutics

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

CLDX
Celldex Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CLDX News

CLDX Celldex Therapeutics Inc.